Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment

Qianqian Zhou; Yanhua Chen; Ruolei Wang; Fengjing Jia; Feng He; Fuwen Yuan

doi:10.1016/j.gendis.2022.11.016

您当前的位置：

首页 >

文章列表页 >

Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment

Review article | 更新时间：2024-02-04

- Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment
- Genes & Diseases Vol. 1, Issue 6, Pages: 2414-2424(2023)
- 作者机构：
  
  Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine,Shanghai,China,201203
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.11.016
  CLC：
- Published：2023，
  
  Published Online：1 November 2023，
扫描看全文
Qianqian Zhou, Yanhua Chen, Ruolei Wang, et al. Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. [J]. Genes & Diseases 1(6):2414-2424(2023)
DOI：

Qianqian Zhou, Yanhua Chen, Ruolei Wang, et al. Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. [J]. Genes & Diseases 1(6):2414-2424(2023) DOI： 10.1016/j.gendis.2022.11.016.

摘要

Abstract

The ongoing global pandemic of coronavirus disease 2019 (COVID-19)

caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

has resulted in over 570 million infections and 6 million deaths worldwide. Early detection and quarantine are essential to arrest the spread of the highly contagious COVID-19. High-risk groups

such as older adults and individuals with comorbidities

can present severe symptoms

including pyrexia

pertussis

and acute respiratory distress syndrome

on SARS-CoV-2 infection that can prove fatal

demonstrating a clear need for high-throughput and sensitive platforms to detect and eliminate SARS-CoV-2. CRISPR-Cas13

an emerging CRISPR system targeting RNA with high specificity and efficiency

has recently drawn much attention for COVID-19 diagnosis and treatment. Here

we summarized the current research progress on CRISPR-Cas13 in COVID-19 diagnosis and treatment and highlight the challenges and future research directions of CRISPR-Cas13 for effectively counteracting COVID-19.

关键词

Keywords

COVID-19CRISPR-Cas13DiagnosisSARS-Cov-2Treatment

references

1 P. Zhou, X.L. Yang, X.G. Wang, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature, 579 (7798) (2020), pp. 270-273

2 J. Harcourt, A. Tamin, X. Lu, et al.Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States Emerg Infect Dis, 26 (6) (2020), pp. 1266-1273

3 F. Wu, S. Zhao, B. Yu, et al.A new coronavirus associated with human respiratory disease in China Nature, 579 (7798) (2020), pp. 265-269

4 R. Arya, S. Kumari, B. Pandey, et al.Structural insights into SARS-CoV-2 proteins J Mol Biol, 433 (2) (2021), p. 166725

5 Y.A. Helmy, M. Fawzy, A. Elaswad, et al.The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control J Clin Med, 9 (4) (2020), p. 1225

6 C.J. Michel, C. Mayer, O. Poch, et al.Characterization of accessory genes in coronavirus genomes Virol J, 17 (2020), p. 131

7 W. Yan, Y. Zheng, X. Zeng, et al.Structural biology of SARS-CoV-2:open the door for novel therapies Signal Transduct Targeted Ther, 7 (2022), p. 26

8 Y. Sun, M. Wang, W. Lin, et al.“mutation blacklist” and “mutation whitelist” of SARS-CoV-2 J Biosaf Biosecurity, 4 (2) (2022), pp. 114-120

9 A. Wilhelm, M. Widera, K. Grikscheit, et al.Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies EBioMedicine, 82 (2022), p. 104158

10 A. Tuekprakhon, R. Nutalai, A. Dijokaite-Guraliuc, et al.Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum Cell, 185 (14) (2022), pp. 2422-2433 e13

11 D. Sanyal, S. Banerjee, A. Bej, et al.An integrated understanding of the evolutionary and structural features of the SARS-CoV-2 spike receptor binding domain (RBD) Int J Biol Macromol, 217 (2022), pp. 492-505

12 S. Dang, L. Ren, J. WangFunctional mutations of SARS-CoV-2:implications to viral transmission, pathogenicity and immune escape Chin Med J, 135 (10) (2022), pp. 1213-1222

13 Q. Wang, Y. Guo, S. Iketani, et al.Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 Nature, 608 (7923) (2022), pp. 603-608

14 Y. Ishino, H. Shinagawa, K. Makino, et al.Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product J Bacteriol, 169 (12) (1987), pp. 5429-5433

15 R. Jansen, J.D. Embden, W. Gaastra, et al.Identification of genes that are associated with DNA repeats in prokaryotes Mol Microbiol, 43 (6) (2002), pp. 1565-1575

16 Y. Ishino, M. Krupovic, P. ForterreHistory of CRISPR-cas from encounter with a mysterious repeated sequence to genome editing technology J Bacteriol, 200 (7) (2018) e00580–17

17 S. Jolany Vangah, C. Katalani, H.A. Booneh, et al.CRISPR-based diagnosis of infectious and noninfectious diseases Biol Proced Online, 22 (2020), p. 22

18 K.S. Makarova, Y.I. Wolf, J. Iranzo, et al.Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants Nat Rev Microbiol, 18 (2) (2020), pp. 67-83

19 S. Shmakov, O.O. Abudayyeh, K.S. Makarova, et al.Discovery and functional characterization of diverse class 2 CRISPR-Cas systems Mol Cell, 60 (3) (2015), pp. 385-397

20 J.S. Gootenberg, O.O. Abudayyeh, J.W. Lee, et al.Nucleic acid detection with CRISPR-Cas13a/C2c2 Science, 356 (6336) (2017), pp. 438-442

21 O.O. Abudayyeh, J.S. Gootenberg, P. Essletzbichler, et al.RNA targeting with CRISPR-cas13 Nature, 550 (7675) (2017), pp. 280-284

22 S. Konermann, P. Lotfy, N.J. Brideau, et al.Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors Cell, 173 (3) (2018), pp. 665-676 e14

23 A.A. Smargon, D.B.T. Cox, N.K. Pyzocha, et al.Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28 Mol Cell, 65 (4) (2017), pp. 618-630 e7

24 D.B.T. Cox, J.S. Gootenberg, O.O. Abudayyeh, et al.RNA editing with CRISPR-Cas13 Science, 358 (6366) (2017), pp. 1019-1027

25 S. Kannan, H. Altae-Tran, X. Jin, et al.Compact RNA editors with small Cas13 proteins Nat Biotechnol, 40 (2) (2022), pp. 194-197

26 C. Xu, Y. Zhou, Q. Xiao, et al.Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes Nat Methods, 18 (5) (2021), pp. 499-506

27 M. Jinek, K. Chylinski, I. Fonfara, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity Science, 337 (6096) (2012), pp. 816-821

28 G. Gasiunas, R. Barrangou, P. Horvath, et al.Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria Proc Natl Acad Sci U S A, 109 (39) (2012), pp. E2579-E2586

29 P. Mali, L. Yang, K.M. Esvelt, et al.RNA-guided human genome engineering via Cas9 Science, 339 (6121) (2013), pp. 823-826

30 L. Cong, F.A. Ran, D. Cox, et al.Multiplex genome engineering using CRISPR/Cas systems Science, 339 (6121) (2013), pp. 819-823

31 H. Zhou, J. Su, X. Hu, et al.Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice Cell, 181 (3) (2020), pp. 590-603 e16

32 L.Z. Yang, Y. Wang, S.Q. Li, et al.Dynamic imaging of RNA in living cells by CRISPR-Cas13 systems Mol Cell, 76 (6) (2019), pp. 981-997 e7

33 Keep off-target effects in focus Nat Med, 24 (8) (2018), p. 1081

34 N. Huynh, N. Depner, R. Larson, et al.A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila Genome Biol, 21 (2020), p. 279

35 V. Anantharaman, K.S. Makarova, A.M. Burroughs, et al.Comprehensive analysis of the HEPN superfamily: identification of novel roles in intra-genomic conflicts, defense, pathogenesis and RNA processing Biol Direct, 8 (2013), p. 15

36 M. Grynberg, H. Erlandsen, A. GodzikHEPN: a common domain in bacterial drug resistance and human neurodegenerative proteins Trends Biochem Sci, 28 (5) (2003), pp. 224-226

37 S.B. Moon, D.Y. Kim, J.H. Ko, et al.Recent advances in the CRISPR genome editing tool set Exp Mol Med, 51 (11) (2019), pp. 1-11

38 S. Tian, B. Zhang, Y. He, et al.CRISPR-iPAS: a novel dCAS13-based method for alternative polyadenylation interference Nucleic Acids Res, 50 (5) (2022), p. e26

39 C. Wilson, P.J. Chen, Z. Miao, et al.Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase Nat Biotechnol, 38 (12) (2020), pp. 1431-1440

40 F. Yuan, W. Hankey, E.J. Wagner, et al.Alternative polyadenylation of mRNA and its role in cancer Genes Dis, 8 (1) (2021), pp. 61-72

41 Z. Cui, C. Zeng, F. Huang, et al.Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection Nat Chem Biol, 18 (10) (2022), pp. 1056-1064

42 H. Tong, J. Huang, Q. Xiao, et al.High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects Nat Biotechnol, 41 (1) (2023), pp. 108-119

43 S. Li, X. Li, W. Xue, et al.Screening for functional circular RNAs using the CRISPR-Cas13 system Nat Methods, 18 (1) (2021), pp. 51-59

44 J.E. Powell, C.K.W. Lim, R. Krishnan, et al.Targeted gene silencing in the nervous system with CRISPR-Cas13 Sci Adv, 8 (3) (2022), Article eabk2485

45 A. Méndez-Mancilla, H.H. Wessels, M. Legut, et al.Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells Cell Chem Biol, 29 (2) (2022), pp. 321-327 e4

46 A.T. He, J. Liu, F. Li, et al.Targeting circular RNAs as a therapeutic approach: current strategies and challenges Signal Transduct Targeted Ther, 6 (2021), p. 185

47 L. Zeng, Y. Liu, X.H. Nguyenla, et al.Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro Nat Commun, 13 (2022), p. 2766

48 P. Chen, M. Chen, Y. Chen, et al.Targeted inhibition of Zika virus infection in human cells by CRISPR-Cas13b Virus Res, 312 (2022), p. 198707

49 X. Zhao, L. Liu, J. Lang, et al.A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment Cancer Lett, 431 (2018), pp. 171-181

50 Y. Chen, H. Jiang, T. Wang, et al.In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system Antivir Res, 178 (2020), p. 104794

51 F. Palaz, A.K. KalkanCan Ö, et al. CRISPR-Cas13 system as a promising and versatile tool for cancer diagnosis, therapy, and research ACS Synth Biol, 10 (6) (2021), pp. 1245-1267

52 L.B. Harrington, D. Burstein, J.S. Chen, et al.Programmed DNA destruction by miniature CRISPR-Cas14 enzymes Science, 362 (6416) (2018), pp. 839-842

53 S.Y. Li, Q.X. Cheng, J.K. Liu, et al.CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA Cell Res, 28 (4) (2018), pp. 491-493

54 Q. Wang, X. Liu, J. Zhou, et al.The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells Adv Sci, 6 (20) (2019), p. 1901299

55 Z. Zhang, Q. Wang, Q. Liu, et al.Dual-locking nanoparticles disrupt the PD-1/PD-L1 pathway for efficient cancer immunotherapy Adv Mater, 31 (51) (2019), Article e1905751

56 B. Zetsche, J.S. Gootenberg, O.O. Abudayyeh, et al.Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-cas system Cell, 163 (3) (2015), pp. 759-771

57 O.O. Abudayyeh, J.S. Gootenberg, S. Konermann, et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector Science, 353 (6299) (2016), p. aaf5573

58 A. East-Seletsky, M.R. O'Connell, S.C. Knight, et al.Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection Nature, 538 (7624) (2016), pp. 270-273

59 J.S. Gootenberg, O.O. Abudayyeh, M.J. Kellner, et al.Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6 Science, 360 (6387) (2018), pp. 439-444

60 J.T. Granados-Riveron, G. Aquino-JarquinCRISPR/Cas13-based approaches for ultrasensitive and specific detection of microRNAs Cells, 10 (7) (2021), p. 1655

61 B. Durán-Vinet, K. Araya-Castro, J. Calderón, et al.CRISPR/Cas13-based platforms for a potential next-generation diagnosis of colorectal cancer through exosomes micro-RNA detection: a review Cancers, 13 (18) (2021), p. 4640

62 M. Broto, M.M. Kaminski, C. Adrianus, et al.Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs Nat Nanotechnol, 17 (10) (2022), pp. 1120-1126

63 R. Bruch, J. Baaske, C. Chatelle, et al.CRISPR/Cas13a-powered electrochemical microfluidic biosensor for nucleic acid amplification-free miRNA diagnostics Adv Mater, 31 (51) (2019), Article e1905311

64 L. Cao, X. Cui, J. Hu, et al.Advances in digital polymerase chain reaction (dPCR) and its emerging biomedical applications Biosens Bioelectron, 90 (2017), pp. 459-474

65 S. Radmard, S. Reid, P. Ciryam, et al.Clinical utilization of the FilmArray meningitis/encephalitis (ME) multiplex polymerase chain reaction (PCR) assay Front Neurol, 10 (2019), p. 281

66 B. Ince, M.K. SezgintürkLateral flow assays for viruses diagnosis: up-to-date technology and future prospects Trends Anal Chem, 157 (2022), p. 116725

67 S. Cavalera, B. Colitti, S. Rosati, et al.A multi-target lateral flow immunoassay enabling the specific and sensitive detection of total antibodies to SARS COV-2 Talanta, 223 (Pt 1) (2021), p. 121737

68 C. Jiao, S. Sharma, G. Dugar, et al.Noncanonical crRNAs derived from host transcripts enable multiplexable RNA detection by Cas9 Science, 372 (6545) (2021), pp. 941-948

69 M.M. Kaminski, O.O. Abudayyeh, J.S. Gootenberg, et al.CRISPR-based diagnostics Nat Biomed Eng, 5 (7) (2021), pp. 643-656

70 T.Y. Liu, G.J. Knott, D.C.J. Smock, et al.Accelerated RNA detection using tandem CRISPR nucleases Nat Chem Biol, 17 (9) (2021), pp. 982-988

71 M. Patchsung, K. Jantarug, A. Pattama, et al.Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA Nat Biomed Eng, 4 (12) (2020), pp. 1140-1149

72 C.L. Fasching, V. Servellita, B. McKay, et al.COVID-19 variant detection with a high-fidelity CRISPR-Cas12 enzyme J Clin Microbiol, 60 (7) (2022), Article e0026122

73 J. Arizti-Sanz, C.A. Freije, A.C. Stanton, et al.Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2 Nat Commun, 11 (2020), p. 5921

74 J.P. Broughton, X. Deng, G. Yu, et al.CRISPR-Cas12-based detection of SARS-CoV-2 Nat Biotechnol, 38 (7) (2020), pp. 870-874

75 C. Myhrvold, C.A. Freije, J.S. Gootenberg, et al.Field-deployable viral diagnostics using CRISPR-Cas13 Science, 360 (6387) (2018), pp. 444-448

76 V. Perčulija, J. Lin, B. Zhang, et al.Functional features and current applications of the RNA-targeting type VI CRISPR-cas systems Adv Sci, 8 (13) (2021), p. 2004685

77 M.J. Kellner, J.G. Koob, J.S. Gootenberg, et al.SHERLOCK: nucleic acid detection with CRISPR nucleases Nat Protoc, 14 (10) (2019), pp. 2986-3012

78 P. Fozouni, S. Son, M. Díaz de León Derby, et al.Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy Cell, 184 (2) (2021), pp. 323-333 e9

79 M. López-Valls, C. Escalona-Noguero, C. Rodríguez-Díaz, et al.CASCADE: naked eye-detection of SARS-CoV-2 using Cas13a and gold nanoparticles Anal Chim Acta, 1205 (2022), p. 339749

80 J. Arizti-Sanz, A. Bradley, Y.B. Zhang, et al.Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants Nat Biomed Eng, 6 (8) (2022), pp. 932-943

81 Evolutionary insight into the emergence of SARS-CoV-2 variants of concern Nat Med, 28 (7) (2022), pp. 1357-1358

82 C. Chakraborty, M. Bhattacharya, A.R. Sharma, et al.Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron GeroScience (2022), pp. 1-22

83 H.H. Wessels, A. Méndez-Mancilla, X. Guo, et al.Massively parallel Cas13 screens reveal principles for guide RNA design Nat Biotechnol, 38 (6) (2020), pp. 722-727

84 C.M. Ackerman, C. Myhrvold, S.G. Thakku, et al.Massively multiplexed nucleic acid detection with Cas13 Nature, 582 (7811) (2020), pp. 277-282

85 N.L. Welch, M. Zhu, C. Hua, et al.Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants Nat Med, 28 (5) (2022), pp. 1083-1094

86 Y. Wang, T. Xue, M. Wang, et al.CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples Sensor Actuator B Chem, 362 (2022), p. 131765

87 Y. Wang, Y. Zhang, J. Chen, et al.Detection of SARS-CoV-2 and its mutated variants via CRISPR-Cas13-based transcription amplification Anal Chem, 93 (7) (2021), pp. 3393-3402

88 E.L. Blanchard, D. Vanover, S.S. Bawage, et al.Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents Nat Biotechnol, 39 (6) (2021), pp. 717-726

89 H. Li, S. Wang, X. Dong, et al.CRISPR-Cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication Mol Ther Nucleic Acids, 19 (2020), pp. 1460-1469

90 J. Cui, N. Techakriengkrai, T. Nedumpun, et al.Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells Sci Rep, 10 (2020), p. 9617

91 M.U. Ashraf, H.M. Salman, M.F. Khalid, et al.CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy Biomed Pharmacother, 136 (2021), p. 111239

92 T.R. Abbott, G. Dhamdhere, Y. Liu, et al.Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza Cell, 181 (4) (2020), pp. 865-876 e12

93 L. Wang, J. Zhou, Q. Wang, et al.Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein Theranostics, 11 (2) (2021), pp. 649-664

94 M. Fareh, W. Zhao, W. Hu, et al.Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance Nat Commun, 12 (1) (2021), p. 4270

95 P.Y. Li, S.Q. Li, S.G. Gao, et al.A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients Med Hypotheses, 159 (2022), p. 110754

96 Z. Glass, M. Lee, Y. Li, et al.Engineering the delivery system for CRISPR-based genome editing Trends Biotechnol, 36 (2) (2018), pp. 173-185

97 C.F. Xu, G.J. Chen, Y.L. Luo, et al.Rational designs of in vivo CRISPR-Cas delivery systems Adv Drug Deliv Rev, 168 (2021), pp. 3-29

98 J. Wei, M.M. Alfajaro, P.C. DeWeirdt, et al.Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection Cell, 184 (1) (2021), pp. 76-91 e13

99 Z. Daniloski, T.X. Jordan, H.H. Wessels, et al.Identification of required host factors for SARS-CoV-2 infection in human cells Cell, 184 (1) (2021), pp. 92-105 e16

100 M. Donoghue, F. Hsieh, E. Baronas, et al.A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circ Res, 87 (5) (2000), pp. E1-E9

101 U. Danilczyk, R. Sarao, C. Remy, et al.Essential role for collectrin in renal amino acid transport Nature, 444 (7122) (2006), pp. 1088-1091

102 T. Liu, S. Luo, P. Libby, et al.Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients Pharmacol Ther, 213 (2020), p. 107587

103 C.B. Jackson, M. Farzan, B. Chen, et al.Mechanisms of SARS-CoV-2 entry into cells Nat Rev Mol Cell Biol, 23 (1) (2022), pp. 3-20

104 S. Matsuyama, N. Nagata, K. Shirato, et al.Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 J Virol, 84 (24) (2010), pp. 12658-12664

105 S.P. Smieszek, B.P. Przychodzen, M.H. PolymeropoulosAmantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment Int J Antimicrob Agents, 55 (6) (2020), p. 106004

106 K. Li, D.K. Meyerholz, J.A. Bartlett, et al.The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19 mBio, 12 (4) (2021), Article e0097021

107 L.B. Baughn, N. Sharma, E. Elhaik, et al.Targeting TMPRSS2 in SARS-CoV-2 infection Mayo Clin Proc, 95 (9) (2020), pp. 1989-1999

108 M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell, 181 (2) (2020), pp. 271-280 e8

109 M.M. Zhao, W.L. Yang, F.Y. Yang, et al.Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development Signal Transduct Targeted Ther, 6 (2021), p. 134

110 T. Shapira, I.A. Monreal, S.P. Dion, et al.A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic Nature, 605 (7909) (2022), pp. 340-348

111 S. Ozono, Y. Zhang, H. Ode, et al.SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity Nat Commun, 12 (2021), p. 848

112 B. Meng, A. Abdullahi, I.A.T.M. Ferreira, et al.Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity Nature, 603 (7902) (2022), pp. 706-714

113 H. Zhao, L. Lu, Z. Peng, et al.SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells Emerg Microb Infect, 11 (1) (2022), pp. 277-283

114 R. Wang, Q. Zhang, J. Ge, et al.Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species Immunity, 54 (7) (2021), pp. 1611-1621 e5

115 P. Padmanabhan, R. Desikan, N.M. DixitTargeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection PLoS Comput Biol, 16 (12) (2020), Article e1008461

116 O. Danziger, R.S. Patel, E.J. DeGrace, et al.Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor PLoS Pathog, 18 (4) (2022), Article e1010464

117 M. Israeli, Y. Finkel, Y. Yahalom-Ronen, et al.Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2 Nat Commun, 13 (2022), p. 2237

118 V. Lotti, F. Merigo, A. Lagni, et al.CFTR modulation reduces SARS-CoV-2 infection in human bronchial epithelial cells Cells, 11 (8) (2022), p. 1347

119 B. Simonetti, J.L. Daly, L. Simón-Gracia, et al.ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1 Proc Natl Acad Sci U S A, 119 (25) (2022), Article e2201980119

120 W. Jiang, H. Li, X. Liu, et al.Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression Theranostics, 10 (25) (2020), pp. 11507-11519

121 L. van Dorp, M. Acman, D. Richard, et al.Emergence of genomic diversity and recurrent mutations in SARS-CoV-2 Infect Genet Evol, 83 (2020), Article 104351

122 H. BrüssowCOVID-19:emergence and mutational diversification of SARS-CoV-2 Microb Biotechnol, 14 (3) (2021), pp. 756-768

123 B. Cosar, Z.Y. Karagulleoglu, S. Unal, et al.SARS-CoV-2 mutations and their viral variants Cytokine Growth Factor Rev, 63 (2022), pp. 10-22

124 S. Li, H. Zhang, L. Zhang, et al.LinearTurboFold: linear-time global prediction of conserved structures for RNA homologs with applications to SARS-CoV-2 Proc Natl Acad Sci U S A, 118 (52) (2021), Article e2116269118

125 X. Lin, Y. Liu, A. Chemparathy, et al.A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses Cell Rep Med, 2 (4) (2021), Article 100245

126 S. Li, H. Wu, L.L. ChenScreening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system Nat Protoc, 17 (9) (2022), pp. 2085-2107

127 D. Yin, L. Yin, J. Wang, et al.Visual detection of duck tembusu virus with CRISPR/Cas13:a sensitive and specific point-of-care detection Front Cell Infect Microbiol, 12 (2022), Article 848365

128 A. Mahas, T. Marsic, M. Lopez-Portillo Masson, et al.Characterization of a thermostable Cas13 enzyme for one-pot detection of SARS-CoV-2 Proc Natl Acad Sci U S A, 119 (28) (2022), Article e2118260119

129 P. Puig-Serra, M.C. Casado-Rosas, M. Martinez-Lage, et al.CRISPR approaches for the diagnosis of human diseases Int J Mol Sci, 23 (3) (2022), p. 1757

130 N.K. Leclair, M. Brugiolo, L. Urbanski, et al.Poison exon splicing regulates a coordinated network of SR protein expression during differentiation and tumorigenesis Mol Cell, 80 (4) (2020), pp. 648-665.e9

131 O.O. Abudayyeh, J.S. Gootenberg, B. Franklin, et al.A cytosine deaminase for programmable single-base RNA editing Science, 365 (6451) (2019), pp. 382-386

132 J. Li, Z. Chen, F. Chen, et al.Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein Nucleic Acids Res, 48 (10) (2020), pp. 5684-5694

133 J. Zhao, B. Li, J. Ma, et al.Photoactivatable RNA N6-methyladenosine editing with CRISPR-Cas13 Small, 16 (30) (2020), Article e1907301

134 H. Cao, Y. Wang, N. Zhang, et al.Progress of CRISPR-Cas13 mediated live-cell RNA imaging and detection of RNA-protein interactions Front Cell Dev Biol, 10 (2022), p. 866820

135 M. Chen, T. Sui, L. Yang, et al.Live imaging of RNA and RNA splicing in mammalian cells via the dcas13a-SunTag-BiFC system Biosens Bioelectron, 204 (2022), p. 114074

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination

Pandemic COVID-19: Current status and challenges of antiviral therapies

Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global pandemic

Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome

Related Author

Sunny Kumar

Malini Basu

Pratyasha Ghosh

Uttam Pal

Mrinal K. Ghosh

Xiaojian Cao

Xiaohua Chen

Yaqi Zhu

Related Institution

Department of Microbiology, Dhruba Chand Halder College, Dakshin Barasat, West Bengal

Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector–V, Salt Lake, Kolkata-700091 & 4, Raja S.C. Mullick Road, Jadavpur, Kolkata

Department of Economics, Bethune College, University of Calcutta, Kolkata

Bio-Medical College, Huazhong Agricultural University

Department of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province

⁰